167 related articles for article (PubMed ID: 36325708)
1. PROGNOSTIC ROLE OF RESIDUAL TUMOR FEATURES IN HER2-NEGATIVE BREAST CANCER.
Sivak LA; Lyalkin SA; Verevkina NO; Shipko AF
Exp Oncol; 2022 Nov; 44(3):222-226. PubMed ID: 36325708
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer.
Zhang L; Wang XI; Zhang S
Hum Pathol; 2018 Oct; 80():47-54. PubMed ID: 29883779
[TBL] [Abstract][Full Text] [Related]
4. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S
Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.
Dieci MV; Criscitiello C; Goubar A; Viale G; Conte P; Guarneri V; Ficarra G; Mathieu MC; Delaloge S; Curigliano G; Andre F
Ann Oncol; 2014 Mar; 25(3):611-618. PubMed ID: 24401929
[TBL] [Abstract][Full Text] [Related]
7. Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis.
Li S; Zhang Y; Zhang P; Xue S; Chen Y; Sun L; Yang R
Breast; 2022 Dec; 66():97-109. PubMed ID: 36219945
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
Liang Y; Lü W; Zhang X; Lü B
Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
[TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis.
Li X; Tan Q; Li H; Yang X
J Surg Oncol; 2021 Jan; 123(1):89-95. PubMed ID: 33047336
[TBL] [Abstract][Full Text] [Related]
11. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
Gao G; Wang Z; Qu X; Zhang Z
BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
[TBL] [Abstract][Full Text] [Related]
13. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
BMC Cancer; 2021 Mar; 21(1):286. PubMed ID: 33726701
[TBL] [Abstract][Full Text] [Related]
15. Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients.
Lusho S; Durando X; Mouret-Reynier MA; Kossai M; Lacrampe N; Molnar I; Penault-Llorca F; Radosevic-Robin N; Abrial C
Front Oncol; 2021; 11():678315. PubMed ID: 34367964
[TBL] [Abstract][Full Text] [Related]
16. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
17. CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer.
Cerbelli B; Botticelli A; Pisano A; Pernazza A; Campagna D; De Luca A; Ascierto PA; Pignataro MG; Pelullo M; Rocca CD; Marchetti P; Fortunato L; Costarelli L; d'Amati G
Virchows Arch; 2020 Apr; 476(4):569-576. PubMed ID: 31853625
[TBL] [Abstract][Full Text] [Related]
18. Effects of tumor-infiltrating lymphocytes on nonresponse rate of neoadjuvant chemotherapy in patients with invasive breast cancer.
Qian XL; Xia XQ; Li YQ; Jia YM; Sun YY; Song YM; Xue HQ; Hao YF; Wang J; Wang XZ; Liu CY; Zhang XM; Zhang LN; Guo XJ
Sci Rep; 2023 Jun; 13(1):9256. PubMed ID: 37286786
[TBL] [Abstract][Full Text] [Related]
19. Tumor infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in relation to pathological complete remission to neoadjuvant therapy and prognosis in triple negative breast cancer.
Zhao M; Xing H; He J; Wang X; Liu Y
Pathol Res Pract; 2023 Aug; 248():154687. PubMed ID: 37478522
[TBL] [Abstract][Full Text] [Related]
20. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.
Criscitiello C; Bayar MA; Curigliano G; Symmans FW; Desmedt C; Bonnefoi H; Sinn B; Pruneri G; Vicier C; Pierga JY; Denkert C; Loibl S; Sotiriou C; Michiels S; André F
Ann Oncol; 2018 Jan; 29(1):162-169. PubMed ID: 29077781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
